GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Asset Turnover

Vincerx Pharma (Vincerx Pharma) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vincerx Pharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Vincerx Pharma's Total Assets for the quarter that ended in Mar. 2024 was $14.65 Mil. Therefore, Vincerx Pharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Vincerx Pharma's annualized ROE % for the quarter that ended in Mar. 2024 was -938.04%. It is also linked to ROA % through Du Pont Formula. Vincerx Pharma's annualized ROA % for the quarter that ended in Mar. 2024 was -339.36%.


Vincerx Pharma Asset Turnover Historical Data

The historical data trend for Vincerx Pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Asset Turnover Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Vincerx Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vincerx Pharma's Asset Turnover

For the Biotechnology subindustry, Vincerx Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vincerx Pharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Asset Turnover falls into.



Vincerx Pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Vincerx Pharma's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (59.286+18.217)/ 2 )
=0/38.7515
=0.00

Vincerx Pharma's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (18.217+11.083)/ 2 )
=0/14.65
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Vincerx Pharma  (NAS:VINC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Vincerx Pharma's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-49.716/5.3
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-49.716 / 0)*(0 / 14.65)*(14.65/ 5.3)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*2.7642
=ROA %*Equity Multiplier
=-339.36 %*2.7642
=-938.04 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Vincerx Pharma's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-49.716/14.65
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-49.716 / 0)*(0 / 14.65)
=Net Margin %*Asset Turnover
= %*0
=-339.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Vincerx Pharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma (Vincerx Pharma) Business Description

Traded in Other Exchanges
N/A
Address
260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054

Vincerx Pharma (Vincerx Pharma) Headlines

From GuruFocus

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 07-06-2022